<DOC>
	<DOCNO>NCT00312286</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 851B gel range concentration dose regimen high-risk cervical human papillomavirus infection woman .</brief_summary>
	<brief_title>Efficacy 851B Gel Treating High-Risk Cervical Human Papillomavirus Infection Women .</brief_title>
	<detailed_description>Cervical cancer cause infection specific genotype human papillomavirus refer oncogenic high-risk human papillomavirus . Current epidemiologic evidence suggest 80 % sexually active woman become infected lifetime human papillomavirus 50 % infection due high-risk human papillomavirus . With US annual rate cervical cancer range 13,000/year , substantial number woman leave uncertainty regard whether infection clear spontaneously progress cancer . Subjects participate study require visit clinic approximately 15 16 visit , maintain diary self-dosing menstruation cycle . The total time participation study approximately 27 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>A female subject childbearing potential sexually active use contraception . Subject willing abstain sexual contact involve genitalia least 24 hour prior 24 hour study drug administration . Subject must neither pregnant lactating Screening throughout duration study . Subject 1 following : Menstruating stable cycle least 21 nonbleeding day . Amenorrheic ( due injectable extendedcycle contraceptive ) . Subject willing refrain use vaginal douche product treatment period Followup Month 4 visit . Subject Pap test interpretation either lowgrade squamous intraepithelial lesion atypical squamous cell undetermined significance . Subject uterine cervical sample highrisk human papillomavirus positive . The Subject evidence uncontrolled , clinically significant medical condition determine investigator . The Subject history hemorrhagic diatheses coagulopathy . The Subject history toxic shock syndrome . The Subject receive follow medication timeframes list : 851 ( form ) active ( nonplacebo ) human papillomavirus vaccine time prior screen visit . In 4 week prior screen visit subject receive : Interferon therapy therapy promote proinflammatory immune state , include : immunomodulators . cytotoxic drug . drug know major organ toxicity . Used vaginal douche 72 hour prior screen visit . Received investigational drug within 60 day Study Day 1 . Used 2 week prior Study Day 1 : oral inhaled corticosteroid ( &gt; 1000 mcg/day , fluticasone propionate &gt; 600 mg/day , equivalent ) . systemic steroid . topical drug anogenital area . NuvaRing . The Subject history hypersensitivity component gel formulation iodine . The Subject give birth spontaneous induced abortion within 2 month Study Day 1 . The Subject use intrauterine device , diaphragm , NuvaRing , additional contraceptive foam gel birth control . The Subject : histology read highgrade cervical intraepithelial neoplasia . cytology read highgrade squamous intraepithelial lesion . cytology read atypical glandular cytological abnormality . cytology read atypical squamous cell exclude high grade . cervical carcinoma type . apparent endocervical involvement . highgrade vulvar intraepithelial neoplasia . highgrade vaginal intraepithelial neoplasia . If limit cervical lesion readily visualize . If limit transformation zone readily visualize . The subject clinical evidence vaginal infection sexually transmitted infection , cervical human papillomavirus infection Study Day 1 visit . The Subject cervical biopsy within 1 month prior screen visit . The Subject previous ablative surgical treatment cervix within 3 month prior screen visit ; The Subject history alcoholism substance abuse within 1 year current alcohol substance abuse assess investigator . The Subject test positive human immunodeficiency virus screen visit evidence immunosuppressive disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cervical Neoplasms</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Human Papillomavirus</keyword>
	<keyword>Cervical Human Papillomavirus</keyword>
	<keyword>Cervical Dysplasia</keyword>
	<keyword>Chemoprevention</keyword>
	<keyword>High Risk Cervical Human Papillomavirus</keyword>
	<keyword>Atypical Squamous Cells Undetermined Significance</keyword>
	<keyword>Low Grade Intraepithelial Lesions</keyword>
</DOC>